Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $9.31 Average PT from Analysts
Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) have been assigned a consensus recommendation of “Buy” from the ten ratings firms that are currently covering the firm, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The […]
Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) have been assigned a consensus recommendation of “Buy” from the ten ratings firms that are currently covering the firm, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The […]
